Slowing Parkinson's disease progression: recent dopamine agonist trials.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 12580184.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In recent clinical trials, chronic treatment of patients with PD with pramipexole or ropinirole was associated with a slower decline of imaged striatal dopaminergic signal, compared to levodopa monotherapy. Although this could reflect slowed progression of PD, equally plausible is a pharmacologic effect on proteins that interact with the imaging radioligands. To date, there is no compelling evidence favoring dopamine agonists over levodopa; either is an appropriate choice for initial treatment of PD.
Medical subject headings
- Antiparkinson Agents
- Dopamine Agonists
- Membrane Glycoproteins
- Nerve Tissue Proteins
- Parkinson Disease